Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT07475325 (E-C-HAU) for Breast Cancer, Invasive Breast Carcinoma is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Back to Search
University Hospital, LilleIndividual Factors Associated With Care Pathways Delays in Breast Cancer in Hauts-de-France. (E-C-HAU) 500 One-Time Treatment
Clinical Trial NCT07475325 (E-C-HAU) is an observational study for Breast Cancer, Invasive Breast Carcinoma and is currently not yet recruiting. Enrollment is planned to begin on 1 March 2026 and continue until the study accrues 500 participants. Led by University Hospital, Lille, this study is expected to complete by 1 March 2028. The latest data from ClinicalTrials.gov was last updated on 23 March 2026.
Brief Summary
Women in the Hauts-de-France region show higher breast cancer mortality despite no overall higher incidence, suggesting differences in the care pathway. This multicenter study will describe the overall time from the first warning sign to initiation of the first treatment, and will break down this delay into three consecutive intervals (symptoms to mammography, mammography to biopsy, biopsy to first treatment). Partic...Show More
Official Title
Behavioral Economics Study of Individual Factors Influencing Time-to-care Among Women With Invasive Breast Cancer in the Hauts-de-France Region
Conditions
Breast CancerInvasive Breast CarcinomaOther Study IDs
- E-C-HAU
- 2025_0354
- 2025-A02030-49 (Other Identifier) (IDRCB)
NCT ID Number
Start Date (Actual)
2026-03
Last Update Posted
2026-03-23
Completion Date (Estimated)
2028-03
Enrollment (Estimated)
500
Study Type
Observational
Status
Not yet recruiting
Keywords
Breast cancer
Diagnostic delay
Time-to-treatment
Patient pathway
Behavioral economics
Diagnostic delay
Time-to-treatment
Patient pathway
Behavioral economics
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Total time from first warning sign to initiation of first treatment. | One-time assessment using patient-reported dates and medical record dates at inclusion (single questionnaire session + record extraction). Questionnaire time : around 1 hour |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Time from first warning sign to first mammography | At inclusion, one-time assessment using patient-reported dates and medical record dates. | |
Time from mammography to biopsy. | At inclusion, one-time assessment using patient-reported dates and medical record dates. | |
Time from biopsy to initiation of first treatment. | At inclusion, one-time assessment using patient-reported dates and medical record dates. | |
To evaluate breast cancer severity at diagnostic. Severity will be assessed by the presence of metastatic disease at diagnosis, recorded as a binary outcome (yes/no) indicating the rate of metastatic at diagnosis | At inclusion, assessed from medical record extraction. | |
To evaluate patients with localized breast cancer, by pronosis estimated using the PREDIC Breast tool. | Pronosis will be reported as 5-year and 10 year estimated survival probabilities, calculated from clinical variables extrected from the medical record at inclusion and expressed on a 0 to 100 % scale, with higher values indicating a better predicted outcome. | At inclusion, calculated using clinical variables extracted from the medical record |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
Female
- Female, age ≥ 18 years.
- Confirmed invasive breast carcinoma.
- Diagnosis in 2024 (and/or < 12 months at inclusion depending on center organization).
- Affiliated with the French social security system.
- Resident of Hauts-de-France since diagnosis.
- Information provided and non-opposition documented (MR-003).
- Male breast cancer.
- Other histologies (phyllodes tumor, sarcoma, lymphoma).
- Pure ductal carcinoma in situ (in situ only).
- Personal history of breast cancer (including in situ).
- Non-French-speaking.
- Person deprived of liberty.
University Hospital, Lille184 active studies to explore- Université de Lille
- Breast Cancer Research Foundation
Study Central Contact
Contact: Nicolas PENEL, PU-PH, 33 320 44 43 63, [email protected]
Contact: Christine LE CLAINCHE, PU, 33 320 41 73 69, [email protected]
34 Study Locations in 1 Countries
Clinique Ste Isabelle, Abbeville, 80100, France
Joël Isapof, MD, Contact, 33 3 22 25 33 33, [email protected]
Joël Isapof, MD, Principal Investigator
CHU Amiens, Amiens, 80054, France
Aurélie Moreira, PH, Contact, 33 3 22 45 54 99, moreira.auré[email protected]
Albine Mancaux, PH, Contact, 33 3 22 08 74 00, [email protected]
Aurélie Moreira, PH, Principal Investigator
Albine Mancaux, PH, Principal Investigator
Clinique Victor Pauchet, Amiens, 80090, France
Joël Isapof, MD, Contact, 33 3 22 33 40 88, [email protected]
Joël Isapof, MD, Principal Investigator
Centre Marie Curie, Arras, 62000, France
Alexandre Henni, MD, Contact, 33 3 21 21 03 29, [email protected]
Alexandre Henni, MD, Principal Investigator
Hôpital privé Les Bonnettes, Arras, 62000, France
Aude Fournier, MD, Contact, 33 3 21 60 20 20, [email protected]
Aude Fournier, MD, Principal Investigator
CH Beauvais, Beauvais, 60000, France
Albine Mancaux, PH, Contact, 33 3 44 11 21 21, [email protected]
Albine Mancaux, PH, Principal Investigator
Centre Pierre Curie, Beuvry, 62321, France
Aurélie Fadin, MD, Contact, 33 3 21 61 92 84, [email protected]
Aurélie Fadin, MD, Principal Investigator
CH Bethune, Béthune, 62408, France
Elvis Nkounkou, PH, Contact, 33 3 64 44 44, [email protected]
Elvis Nkounkou, PH, Principal Investigator
CH Boulogne, Boulogne, 62321, France
Benoït Desgrousilliers, MD, Contact, 33 3 21 99 30 13, [email protected]
Benoît Desgrousilliers, MD, Principal Investigator
CH Calais, Calais, 62107, France
Margaux Becard, PH, Contact, 33 3 21 46 17 54, [email protected]
Margaux Becard, PH, Principal Investigator
CH Chauny, Chauny, 02300, France
Marc Kanaan, PH, Contact, 33 3 23 38 53 89, [email protected]
Marc Kanaan, PH, Principal Investigator
Centre de Radiothérapie de Compiègne, Compiègne, 60200, France
Guillaume Dupic, MD, Contact, 33 3 44 96 10 00, [email protected]
Guillaume Dupic, MD, Principal Investigator
Polyclinique St Côme, Compiègne, 60200, France
Kais Aldabbagh, MD, Contact, 33 3 44 92 43 53, [email protected]
Kais Aldabaggh, MD, Principal Investigator
CH Compiègne, Compiègne, 60321, France
Riccardo Samaritani, PH, Contact, 33 3 44 23 66 73, [email protected]
Riccardo Samaritani, PH, Principal Investigator
Clinique de Flandre, Coudekerque-Branche, 59210, France
Jean Baptiste Ainsenfarb, MD, Contact, 33 3 28 28 14 39, [email protected]
Jean Baptiste Aisenfarb, MD, Principal Investigator
Centre de Radiothérapie de Creil, Creil, 60100, France
Pierre Maroun, MD, Contact, 33 3 44 28 41 00, [email protected]
Pierre Maroun, MD, Principal Investigator
Centre Leonard de Vinci, Dechy, 59187, France
Natacha Stern, MD, Contact, 33 3 27 08 60 60, [email protected]
Natacha Stern, MD, Principal Investigator
Polyclinique de la Clarence, Divion, 62460, France
Maïté Smail, PH, Contact, 33 3 21 54 92 68, [email protected]
Maïté Smail, PH, Principal Investigator
Institut Andrée Dutreix, Dunkirk, 59240, France
Jean Baptiste Aisenfarb, MD, Contact, 33 3 28 51 96 30, [email protected]
Jean Baptiste Aisenfarb, MD, Principal Investigator
CH Dunkerque, Dunkirk, 59385, France
Lilia Bougherara, PH, Contact, 33 3 28 51 96 30, [email protected]
Lilia Bougherara, PH, Principal Investigator
Polyclinique d'Hénin-Beaumont, Hénin-Beaumont, 62254, France
Daphné Borja De Mozota, MD, Contact, 33 3 21 13 32 88, [email protected]
Daphné Borja De Mozota, MD, Principal Investigator
CH Lens, Lens, 62300, France
Alice Pham Becker, PH, Contact, 33 3 21 69 16 74, [email protected]
Alice Pham Becker, PH, Principal Investigator
Centre Oscar Lambret, Lille, 59000, France
Audrey Mailliez, MD, Contact, 33 3 20 29 59 59, [email protected]
Audrey MAILLIEZ, MD, Principal Investigator
Hôpital privé Le Bois, Lille, 59000, France
Margaux Lesage, MD, Contact, 33 3 20 01 08 55, [email protected]
Margaux Lesage, MD, Principal Investigator
Hôpital St Vincent, Lille, 59000, France
Sylvie Berger, MD, Contact, 33 3 20 87 45 32, [email protected]
Sylvie Berger, MD, Principal Investigator
CHU Lille, Lille, 59037, France
Yohan KERBAGE, MCU-PH, Contact, 33 3 20 44 67 99, [email protected]
Marie PECOUT, PH, Contact, 33 3 20 44 59 62, [email protected]
Marie PECOUT, PH, Principal Investigator
Yohan Kerbage, MCU-PH, Principal Investigator
Centre Gray, Maubeuge, 59600, France
Laurent Gilbeau, MD, Contact, 33 3 27 69 89 83, [email protected]
Laurent Gilbeau, MD, Principal Investigator
CH Roubaix, Roubaix, 59100, France
Claire Migne, PH, Contact, 33 3 20 99 32 43, [email protected]
Claire Migne, PH, Principal Investigator
CH St Quentin, Saint-Quentin, 02321, France
Patrick Theret, PH, Contact, 33 3 23 06 71 71, [email protected]
Patrick Theret, PH, Principal Investigator
CH Soissons, Soissons, 02200, France
Sarah Montembault, PH, Contact, 33 3 23 75 70 70, [email protected]
Sarah Montembault, PH, Principal Investigator
Clinique de la Victoire, Tourcoing, 59200, France
Margaux Lesage, MD, Contact, 33 3 59 75 87 58, [email protected]
Margaux Lesage, MD, Principal Investigator
CH Tourcoing, Tourcoing, 59208, France
Anne Deniel, PH, Contact, 33 3 20 69 47 47, [email protected]
Anne Deniel, PH, Principal Investigator
Clinique des dentellières, Valenciennes, 59300, France
Géraldine Lauridant, MD, Contact, 33 3 27 09 10 10, [email protected]
Géraldine Lauridant, MD, Principal Investigator
CH Valenciennes, Valenciennes, 59322, France
Sébastien Borges, PH, Contact, 33 3 27 14 05 40, [email protected]
Sébastien Borges, PH, Principal Investigator